BASi hosts in vivo drug discovery workshop at UCLA
Published: May 30, 2014
WEST LAFAYETTE, Ind. - Bioanalytical Systems Inc. announced that it hosted a workshop yesterday at UCLA designed to help academic researchers efficiently navigate the in vivo study process that is the foundation of drug discovery, lead compound optimization, and the early phases of regulated drug development.
Candace Rohde-Johnson, Director, Instruments Division at BASi, explained, "In addition to an overview of the drug discovery process, the workshop focused on effectively designing in vivo studies. We covered Good Laboratory Practice (GLP) and non-GLP study designs, as well as model selection, formulation, dosing and sampling methods, group size selection and general study designs for both discovery and pre-clinical studies. The workshop placed special emphasis on study designs that minimize subject discomfort--resulting in better studies overall, and streamlining the path to the ultimate filing of an IND."
BASi President, CEO and CFO Jacqueline Lemke added, "This workshop builds on BASi's recognized strengths in specialty assay and drug discovery, regulatory excellence, and our Culex® automated sampling system. Culex can automatically collect blood, bile, metabolites, dialysates and more from awake and freely moving subjects as small as mice and as large as swine. In contrast to traditional manual sampling, Culex automated sampling saves time, saves money and saves lives while providing better data for studies in pharmacokinetics, drug metabolism and toxicology.
"This workshop at UCLA was the latest step in our effort to expand BASi's reach into the academic drug development community as well as the many smaller, specialty drug development organizations that generally do not have the extensive scientific and regulatory capabilities required to move a drug candidate through the arduous FDA approval process. With BASi's 40-year history of providing world-class research to the pharmaceutical industry, our drug discovery services and proprietary instruments can make a real difference in facilitating the drug development process."
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.
SOURCE: Bioanalytical Systems, Inc.
Bioanalytical Systems, Inc.
Jacqueline Lemke, President, CEO and CFO
Neil Berkman, 310-477-3118